Agoracom Blog Home

Posts Tagged ‘$TSXV’

Canadian #Marijuana awards show lights up with first-ever gala #MMJ $TBP.ca $N.ca $MCOA

Posted by AGORACOM-JC at 10:48 AM on Thursday, November 30th, 2017
  • You know marijuana is going mainstream when the list of attendees who reserved tables reads like a who’s who of Canada’s haze of law and accounting firms, including Torys LLP, Dentons, Cassels Brock & Blackwell LLP, Bennett Jones LLP, investment dealer Eight Capital and accounting giants KPMG and MNP
By Lisa WrightBusiness Reporter
Wed., Nov. 29, 2017

What do you do if you’re a budding awards show trying to create a buzz around Canada’s $8.7-billion cannabis market?

First you weed out the best producers from the very large crop of products out there. Then you book a swanky joint and roll out the red carpet for business types looking to get in on the potential pot of gold surrounding legalization next summer.

The CEO of Lift Co., the online marketplace for the medical marijuana industry that is holding the event, says it was high time for a grass gala to highlight the fourth annual Canadian Cannabis Awards – previously held only online – in an effort to add some legitimacy to the often stigmatized cannabis community.

“It’s really going to be a mini Oscars” of pot, said Matei Olaru of the awards show being held Thursday night at the historic Carlu at College Park.

You know marijuana is going mainstream when the list of attendees who reserved tables reads like a who’s who of Canada’s haze of law and accounting firms, including Torys LLP, Dentons, Cassels Brock & Blackwell LLP, Bennett Jones LLP, investment dealer Eight Capital and accounting giants KPMG and MNP.

“These are recognizable names excited to be associated publicly with the industry,” said Olaru.

“The industry has matured enough and there are enough players, so it’s the right time for this,” he added.

In fact they will hand out a whopping 75 awards to producers and numerous other players in the marijuana business during an evening of cocktails and plenty of munchies over a sit-down dinner. The laughs will officially be provided by famed comedian twins The Lucas Brothers of 22 Jump Street and Netflix fame, who will be performing standup before the after party.

Categories range from the traditional — employer of the year, startup of the year, innovator of the year, deal of the year and even lifetime achievement award — to the offbeat, including the best in show of vape lounges, cannabis chefs, desktop and portable vaporizers, top testing lab and best home growing box.

“It’s a way to showcase those achievements,” said Olaru, whose mission is to demystify the continued confusion around the medical marijuana market as it grows like a weed.

For instance pot smoking rapper Snoop Dogg recently partnered with Canadian licensed producer Tweed, which is nominated in multiple categories.

Another sign that legalization is around the corner is Lift landing official support this week from MADD Canada as it develops Canada’s first retail training certification program for frontline staff at cannabis retailers who will have legal storefronts as of July 2018.

“Our experience with alcohol sales has shown that having comprehensive training and responsible service guidelines for front-line staff is crucial to reducing alcohol-related harms, including impaired driving,” says MADD Canada chief executive officer Andrew Murie.

“The same will be true of cannabis retail sales. MADD Canada is pleased to partner with a leader like Lift and support this program, which will ensure that all those involved in the retail sales of cannabis are well-trained about the products, about safe usage guidelines and about social responsibility principles,” he said in a release.

Source: https://www.thestar.com/business/2017/11/29/canadian-marijuana-awards-show-lights-up-with-first-ever-gala.html

Alibaba $BABA betting on long-term gain from #Esports investment, bodes well for $GMBL $ATVI $TTWO $GAME $EPY.ca

Posted by AGORACOM-JC at 10:16 AM on Thursday, November 30th, 2017

  • Chinese e-commerce conglomerate Alibaba believes it is only a matter of time before its bet on competitive video gaming comes up big
  • Alibaba’s sports arm Alisports was opened in 2015 with the aim of cashing in on the rapidly growing world of electronic sports, where players square off in lucrative video game tournaments that draw millions of viewers online

BARCELONA: The booming eSports industry may not yet attract the sponsors and television rights of real life sports, but Chinese e-commerce conglomerate Alibaba believes it is only a matter of time before its bet on competitive video gaming comes up big.

Alibaba’s sports arm Alisports was opened in 2015 with the aim of cashing in on the rapidly growing world of electronic sports, where players square off in lucrative video game tournaments that draw millions of viewers online.

“We are prepared to lose money. We can accept the losses now as we hope to promote this sport,” Alisports CEO Zhang Dazhong told AFP in an interview at the European final of the second edition of Alisports’ World Electronic Sports Games (WESG) in Barcelona, which wrapped up on Sunday (Nov 26).

“For a sport that has a lot of participation, it must have a bright future. Even if for now you don’t make a lot of money, in the future, you’ll definitely be rewarded. This is something we firmly believe in.”

In 2016, Alisports entered into an agreement with the International e-Sports Federation (IeSF) to create the WESG, a market-leading international tournament.

The first edition of the WESG saw 63,000 participants from 125 countries battle for a share of the US$5.5 million prize pot.

Yet the results weren’t so lucrative for Alisports, who lost 70 per cent of their investment.

“We estimate that we will be losing money for the next five years,” admitted Zhang.

LONG-TERM RETURNS

Alisports’ strategy, though, is a long-term one.

“We estimate that in five to ten years … the business model will be more complete. On top of the competitions, we have to bear in mind the electronics business and marketing related to eSports,” added Zhang.

Participation in eSports has soared as virtual games gain traction with a worldwide fan audience now estimated at 400 million people according to a study by Deloitte, more than that for baseball or American football’s National Football League.

The size of the eSports market will more than double to US$696 million this year from US$325 million in 2015, according to Deloitte’s study. It predicts the market will be worth US$1.5 billion in 2020.

But the market is fragmented, with different operators staging their own tournaments, and sales of television rights and merchandising remain weak.

An eSport fan brings only three euros to the table annually on average, according to a recent study by market research group Nielsen Sports, compared to 30 euros for a football fan.

Yet, Alibaba believes its position as the market leader in China, the worldwide powerhouse of eSports, ensures the return on eSports will be plentiful.

“In China we have 1.8 million eSport fanatics and 65 per cent of those are between 18 and 25,” continued Zhang.

“They play video games, but they also buy all sorts of products from Alibaba. We understand them very well.”

OLYMPIC DREAM?

The leap in popularity has helped fuel talk that professional gaming could become an Olympic discipline, but not everyone is convinced.

“I think we have to differentiate eSports and gaming in general,” Zhang said when he was asked about the controversy.

“Gaming of course isn’t a sport, but eSports involve high-level confrontation, teams, individual resistance, so I think it’s a sport. And I think that sport in general is evolving towards a combination of technology and physical activity.”

Zhang said he hopes eSports will be part of the 2024 Olympics in Paris or the 2028 Olympics in Los Angeles.

“It could happen, because at this year’s Asian Indoor and Martial Arts Games, we already gave a demonstration of games. In the Asian Games in Hangzhou in 2022, it’s already an official event,” he said.

The director of the Paris 2024 Olympics committee said earlier this month that the door to the Games was “not closed” to eSports.

Source: AFP/zl

Read more at http://www.channelnewsasia.com/news/business/alibaba-betting-on-long-term-gain-from-esports-investment-9453652

Marijuana Company of America $MCOA Partners with #HoneyB Healthy Living to Launch the #Benihemp Brand $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:54 AM on Thursday, November 30th, 2017

15233 mcoa

  • Announced that it has partnered with the founders of HoneyB Healthy Living to develop Convenient Hemp Mart, LLC’s “BeniHemp” branded products
  • Targeting convenience stores for CBD product distribution. MCOA has invested $100,000 into the start-up project for a 25% equity stake.

Escondido, California–(November 30, 2017) – MARIJUANA COMPANY OF AMERICA INC. (OTC: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis company, is pleased to announce that it has partnered with the founders of HoneyB Healthy Living to develop Convenient Hemp Mart, LLC’s “BeniHemp” branded products targeting convenience stores for CBD product distribution. MCOA has invested $100,000 into the start-up project for a 25% equity stake.

BeniHemp products includes topicals, tinctures and edibles conveniently packaged in 1-day, 2-day and 30-day supplies. The target markets are convenience stores, smoke shops, gas stations and similar types of small retail businesses where CBD commerce has significant potential to generate sales from the impulse buyer at the register.

Convenient Hemp Mart is in the process of developing unique sample sized packaging for consumers to try its BeniHemp products. When customers have a positive experience with BeniHemp sample products, they will then be able to purchase a monthly supply and sign up for auto ship online. Store owners will continue to generate additional revenue without the burden of managing inventory and shelf space.

MCOA Chief Executive Officer Donald Steinberg observed: “The BeniHemp model is attractive to convenience store operators, who understand the value of selling sample sized packages of CBD products that will ultimately generate online sales for monthly orders where they can generate revenues from sales they never see or have to manage. We believe this is an attractive model for small retail business owners looking for every opportunity to tap into the rapidly emerging CBD market to generate additional revenue. We have high expectations for what the experienced HoneyB team can accomplish.”

HoneyB Healthy Living and Convenient Hemp Mart are working with MCOA and Space Cowboys, Inc. in Loveland and Longmont Colorado to establish a secure and consistent supply of quality cannabinoids to fulfill demand for current and future product development and distribution.

The expectation is that BeniHemp will soft launch in December 2017 with the full launch in January 2018. The BeniHemp website is in development and will be launched in January as well. Benihemp products have already been manufactured are pending shipment once the package designs, including counter top displays, floor displays and related marketing materials are complete.

Frank Phillips, Conveniant Hemp Mart’s Chief Executive Officer commented: “We are extremely excited to come to market with the very highest quality products designed specifically for curious first-time cannabinoid users. The CBD market is experiencing exponential growth and we intend to capture market share in one of the highest trafficked marketplaces, convenience stores. Because of the expertise of Space Cowboys in producing some of the highest quality hemp oil on the market, and the proven manufacturing and formulation abilities of our Honey B Healthy Living team, we believe that our introductory products coming to convenience store shelves will generate considerable traffic to our online portals for monthly order placements creating an absolute win for the stores carrying our products.”

About Marijuana Company of America, Inc.
MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
[email protected]

Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

$AAO.ca Augusta Announces Results for the Third Quarter and Corporate Update $PHO.ca

Posted by AGORACOM at 9:17 AM on Thursday, November 30th, 2017

 

  • Revenue of $650,000 as compared to $1,479,000 during the three months ending September 30, 2016
  • Marcon group backlog sales as on the date of the MD&A is $1,988,000
  • Gross margins were 21% compared to 13% for the three months ending September 30, 2016

Toronto, Ontario–(Newsfile Corp. – November 30, 2017) – Augusta Industries Inc. (TSXV: AAO) (the “Corporation”) is pleased to announce that it has released its financial results for the nine months ending September 30, 2017.

For the three months ending September 30, 2017, the Corporation had revenues of $650,000 as compared to $1,479,000 during the three months ending September 30, 2016. Marcon group backlog sales as on the date of the MD&A is $1,988,000. Four of the backlog orders worth $1,723,000 have a long delivery lead time. The Corporation also expects to build on the two contracts signed in 2017 by FOX-TEK worth $1,039,000 over a three year period.

Total loss from operations for the three months ending September 30, 2017 was $160,000 or a net loss of $0.001 per share compared to a loss of $74,000 or $0.000 per share for the three months ending September 30, 2016. Gross margins for the three months ending September 30, 2017 was 21% compared to 13% for the three months ending September 30, 2016 due to the change in mix between Macron and FOX-TEK sales during the period . The operating expenses in the three months ending September 30, 2017 was slightly less at $251,000 compared to $255,000 for the same period in 2016. Stock based compensation during the three months ending September 30, 2017 was $47,000 while there were no such expenses during the three months ending September 30, 2016.

Marcon group sales in the three months ending September 30, 2017 was $564,000 compared to $1,394,000 in the three months ending September 30, 2016 – a decrease of $830,000. The sales in FOX-TEK for the three months ending September 30, 2017 were $86,000 close to $85,000 sales for the three months ending September 30, 2016.


 

The financial statements, notes to the financial statements and Management’s Discussion and Analysis for the nine months ending September 30, 2017 are available on SEDAR at www.sedar.com.

Corporate Update – Business Development

Please see section on Business Development (Page 5 ) in the MD&A for the nine months ended September 30, 2017 for details.

About the Corporation:

Through its wholly owned subsidiaries, Marcon International Inc. (“Marcon”) and Fox-Tek Canada Inc. (“Fox-Tek”), the Corporation provides a variety of services and products to a number of clients.

Marcon is an industrial supply contractor servicing the energy sector and a number of US Government entities. Marcon’s principal business is the sale and distribution of industrial parts and equipment (Electrical, mechanical and Instrumentation.) In addition to departments and agencies of the U.S. Government, Marcon’s major clients include Saudi Arabia-Sabic Services (Refining and Petrochemical), Bahrain National Gas Co, Bahrain Petroleum, Qatar Petroleum, Qatar Gas, Qatar Petrochemical, Gulf of Suez Petroleum, Agiba Petroleum and Burullus Gas Co.

Fox Tek develops non-intrusive asset health monitoring sensor systems for the oil and gas market to help operators track the thinning of pipelines and refinery vessels due to corrosion/erosion, strain due to bending/buckling and process pressure and temperature. The Corporation’s FT fiber optic sensor and corrosion monitoring systems allow cost-effective, 24/7 remote monitoring capabilities to improve scheduled maintenance operations, avoid unnecessary shutdowns, and prevent accidents and leaks.

Corporation contact:

Allen Lone, President, CEO, Augusta Industries Inc.
Tel: (905) 275 -8111 Ext 226 email: [email protected]

The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and as neither approved nor disapproved the contents of this press release.

AGORACOM INTERVIEW: Why Namaste $N.ca Divested Its’ US Assets and Why It Is Now The Amazon “Plus” Of The #Marijuana Space $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 7:45 AM on Thursday, November 30th, 2017

Namaste released news yesterday morning that it was divesting of its’ US operations.  The move would clear hurdles around major partnerships, financing and uplisting created by the political uncertainty surrounding the legalization of cannabis in the US.  Following the company’s conference call this morning, AGORACOM sat down with CEO Sean Dollinger to discuss the major advantages and opportunities that would arise as a result of divesting US operations, including:

    • Partnership discussions with Licensed Producers (LPs)
    • Investments by LPs
    • Attracting large institutional investors
    • Listing on the TSX Venture Exchange

We then switched our focus to current operations and upcoming events, including:

  • A 500% increase in Black Friday /  Cyber Monday sales
  • The imminent approval of its’ CannMart Medical Marijuana License
  • NamasteMD launch on December 11
  • Why Namaste is now the Amazon Of The Marijuana Space
  • Why investors need to understand the long-term picture and stop looking at the tape

 

ThreeD Capital Inc. $IDK.ca Acquires Securities of Global Cannabis Applications Corp.$APP.ca $ATT.ca $ABCN.ca $ACG.ca $ACB

Posted by AGORACOM-JC at 9:36 AM on Wednesday, November 29th, 2017

Threed capital

  • Acquired ownership and control of an aggregate of 1,000,000 common shares and 1,000,000 common share purchase warrants of Global Cannabis Applications Corp. 
  • Immediately before the transaction described above, ThreeD and the Joint Actor held an aggregate of 4,850,000 common shares of the Company, and convertible securities entitling ThreeD and the Joint Actor to acquire an additional 2,250,000 common shares of the Company

TORONTO, Nov. 29, 2017 – ThreeD Capital Inc. (“ThreeD”) (CSE:IDK) is pleased to announce that it has acquired ownership and control of an aggregate of 1,000,000 common shares (the “Subject Shares”) and 1,000,000 common share purchase warrants (the “Subject Warrants” and together with the Subject Shares, the “Subject Units”) of Global Cannabis Applications Corp. (the “Company”) on November 28, 2017.  The Subject Units represented approximately 1.7% of all issued and outstanding common shares of the Company as of November 28, 2017 immediately following the transaction described above (or approximately 3.4% on a partially diluted basis, assuming exercise of the Subject Warrants only), resulting in a corresponding increase in the percentage of shares held by ThreeD and its Joint Actor as a result of the transaction.

Immediately before the transaction described above, ThreeD and the Joint Actor held an aggregate of 4,850,000 common shares of the Company (the “Pre-Shares”), and convertible securities entitling ThreeD and the Joint Actor to acquire an additional 2,250,000 common shares of the Company (the “Pre-Convertible Securities”) representing approximately 9.0% of the issued and outstanding common shares of the Company (or approximately 12.6% on a partially diluted basis, assuming exercise of the Pre-Convertible Securities only).  Of this total, ThreeD held an aggregate of 3,000,000 of the Pre-Shares and 2,000,000 Pre-Convertible Securities, representing approximately 5.6% of the issued and outstanding common shares of the Company (or approximately 8.9% assuming exercise of such Pre-Convertible Securities only), and the Joint Actor held an aggregate of 1,850,000 of the Pre-Shares and 250,000 Pre-Convertible Securities, representing approximately 3.4% of the issued and outstanding common shares of the Company (or approximately 3.9% on a partially diluted basis, assuming exercise of such Pre-Convertible Securities only).

Immediately following the transaction described above, ThreeD and the Joint Actor held an aggregate of 5,850,000 common shares (the “Post-Closing Shares”) and convertible securities entitling ThreeD and the Joint Actor to acquire an additional 3,250,000 common shares of the Company (the “Post-Closing Convertible Securities”), representing approximately 10.2% of the issued and outstanding common shares of the Company (or approximately 15.0% assuming exercise of such Post-Closing Convertible Securities only).  Of this total, ThreeD held an aggregate of 4,000,000 of the Post-Closing Shares and 3,000,000 of the Post-Closing Convertible Securities (representing approximately 7.0% of the issued and outstanding common shares of the Company, or approximately 11.6% assuming exercise of such Post-Closing Convertible Securities only), and the Joint Actor held an aggregate of 1,850,000 of the Post-Closing Shares and 250,000 of the Post-Closing Convertible Securities, representing approximately 3.2% of the issued and outstanding common shares of the Company (or approximately 3.6% on a partially diluted basis, assuming exercise of such Post-Convertible Securities only).

The Subject Units were acquired in a private placement and not through the facilities of any stock exchange.  The holdings of securities of the Company by ThreeD and the Joint Actor are managed for investment purposes, and ThreeD and the Joint Actor could increase or decrease their investments in the Company at any time, or continue to maintain their current investment position, depending on market conditions or any other relevant factor. The aggregate consideration payable for the Subject Units was $135,000, or $0.135 per Subject Unit.

The trade was effected in reliance upon the exemption contained in Section 2.3 of National Instrument 45-106 on the basis that each of ThreeD and the Joint Actor is an “accredited investor” as defined herein.

About ThreeD Capital Inc.

ThreeD Capital Inc. is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources, Artificial Intelligence and Blockchain sectors.

ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company’s network in order to earn increases to the Company’s equity stake.

For further information: Gerry Feldman, CPA, CA Chief Financial Officer and Corporate Secretary
[email protected] Phone: 416-606-7655

Namaste $N.ca Divests US Assets to Focus on Legal #Cannabis Markets and Announces Conference Call $ATT.ca $ABCN.ca $ACG.ca $ACB

Posted by AGORACOM-JC at 5:52 PM on Tuesday, November 28th, 2017

Nlogo

  • Will sell the Company’s wholly owned US subsidiary, Dollinger Enterprises US Inc
  • Agreement includes the sale of the domain names Everyonedoesit.com and NamasteVapes.com which combined represent less than 7% of Namaste’s current gross revenue,
  • Both of which are currently operating at a net loss

VANCOUVER, British Columbia, Nov. 28, 2017 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (OTCQB:NXTTF) (FRANKFURT:M5BQ) is pleased to announce that it has signed a stock purchase agreement (the “Agreement”) with ESC Hughes Holdings Limited (“ESC”) to sell the Company’s wholly owned US subsidiary, Dollinger Enterprises US Inc. (“Dollinger US”). The Agreement includes the sale of the domain names Everyonedoesit.com and NamasteVapes.com which combined represent less than 7% of Namaste’s current gross revenue, both of which are currently operating at a net loss. Due to the political uncertainty surrounding the legalization of cannabis in the US, Namaste’s management has deemed it appropriate to shift its focus to legal cannabis markets and management believes that the Company will be better aligned with its long-term interests by divesting its US operations. Management also feels it is prudent to divest these assets in preparation for the legalization of both medical and recreational marijuana in Canada. This decision better aligns Namaste with many of its Canadian counterparts and will enable the Company to capitalize on more accretive opportunities moving forward.

Under the terms of the Agreement, Namaste will, through its wholly owned subsidiary, Namaste Technologies Holdings Inc., in consideration of a cash purchase price of US $400,000, convey to ESC the following:

  • All authorized and issued shares of Dollinger US
  • NamasteVapes.com and Everyonedoesit.com domains
  • All banking, merchant, and services accounts
  • Five employees of Dollinger US
  • One real estate lease held under Dollinger US

Payment of US $100,000 will be received on closing, with the balance of the purchase price being paid at a monthly rate of US $25,000 until paid in full, with payments commencing on January 1, 2018. Closing is expected to occur on or about December 4, 2017.

Although many US states have established some form of medical and/or recreational cannabis legalization, the US federal government remains firm on its position regarding cannabis prohibition. Namaste feels this uncertainty may pose challenges in both the short and medium term and restrict growth opportunities in more progressive markets. Under the terms of this Agreement, Namaste will retain all of its existing database of over 520,000 US consumers, and intends on leveraging that data once US federal legalization is in place.

Namaste believes that Canada is at the forefront of the industry for cannabis legalization and intends to leverage its expertise to become the country’s leading online retailer for medical cannabis. By divesting itself of its US assets and operations, Namaste intends to reposition its focus in an attempt to fuel efficiency and growth. Through its wholly owned subsidiary, Cannmart Inc. (“CannMart”), Namaste is near approval for a license and plans to distribute medical cannabis through its online telemedicine app known as NamasteMD. Once approval is received, Namaste, through CannMart, will be able to leverage all of its e-commerce expertise, resources, and technology to become Canada’s leading e-commerce platform for medical cannabis sales. Namaste’s management team intends to pursue similar opportunities in distribution of legal cannabis in other markets where the Company has already established strong market share such as Australia and various countries in the EU.

Conference Call
Namaste will be holding a conference call at 8:30 a.m. on Wednesday, November 29, 2017 to discuss and answer questions regarding the above news. The call will be led by Namaste’s CEO, Sean Dollinger. In order to join the conference call, participants may dial the toll-free number below with the accompanying Event Passcode:

Participant Event Plus Toll Free Dial-In Number: (844) 862-1432
Participant Event Plus Toll Dial-In Number: (702) 495-1535

Event Passcode: 3396668

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “In light of recent trends, Namaste is extremely excited at the potential for additional growth opportunities in more progressive markets. As a result of this divestiture, Namaste believes it has set the stage to fully exploit any and all opportunities that present themselves within legalized marijuana markets globally. Our decision to divest these US assets is strategic in nature and sets the stage for greater expansion of our e-commerce platform. Namaste believes its future success will be achieved through organic growth, in addition to forming strategic alliances. We also believe this divestiture will lead the Company to profitability in a much shorter time-frame.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the Access to Cannabis for Medical Purposes Regulations Program) is pursuing a new revenue vertical in online sales of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:
www.namastetechnologies.com
www.namastevaporizers.com
www.namastevaporizers.co.uk
www.everyonedoesit.com
www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Tetra Bio-Pharma $TBP.ca accelerates submission of New Drug Application to FDA & Expects to Commercialize Dronabinol XL Tablet Ahead of Schedule in the US $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 5:29 PM on Tuesday, November 28th, 2017

Logo tetrabiopharma rgb web

  • Announced that it is partnering with a major manufacturer of controlled active pharmaceutical ingredients (APIs) in the USA for the manufacturing of Dronabinol XL AdVersa® 
  • Company accelerates its plans to submit a 505(b)(2) New Drug Application for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS

OTTAWA, ONTARIO–(Nov. 28, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it is partnering with a major manufacturer of controlled active pharmaceutical ingredients (APIs) in the USA for the manufacturing of Dronabinol XL AdVersa® as the Company accelerates its plans to submit a 505(b)(2) New Drug Application (NDA) for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS.

According to market research by the International Agency for Research on Cancer 2, the global chemotherapy-induced nausea and vomiting (CINV) market will reach a valuation of US$1.88 bn by 2020, rising from its 2013 valuation of US$1.28 bn. Based on the expected improved safety profile of a delayed release Dronabinol, Tetra expects that the Adversa® tablet can gain an important share of this market within three (3) years of its launch in the USA, with sales of Adversa® that could potentially reach $30,000,000 USD at the end of the third year of sales.

In March 2017, Tetra licensed the Dronabinol XL AdVersa® technology from IntelGenx and entered into a co-development agreement to bring this controlled release formulation of Dronabinol (tetrahydrocannabinol; THC) to the market. Tetra is looking to accelerate its commercialization plans in the USA by seeking marketing approval by the Food and Drug Administration (FDA) for the following therapeutic indications, which are identical to those of Marinol® (dronabinol capsules): “Use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.” It’s buccal administration in cases of nausea makes it an attractive therapeutic option for cancer patients.

Tetra’s partnership with a major manufacturer in the USA that has been manufacturing dronabinol for years to develop the commercial manufacturing of this innovative patent-protected new drug is key in its submission to the FDA. The submission of an NDA under 505(b)(2) to the U.S. Food and Drug Administration (FDA) requires demonstration that the new controlled release formulation provides similar systemic exposure to the listed/approved drug dronabinol. The data generated by IntelGenx demonstrated that the new formulation increases bioavailability of the THC and the new route of administration results in a lower level of the metabolite 11-hydroxy THC. The implications are that a lower dose of THC will be required. The Dronabinol XL AdVersa® formulation is absorbed by the buccal mucosa thereby limiting exposure to the gastrointestinal tract. These differentiating points, along with other characteristics of the new drug Dronabinol XL AdVersa®, are expected to result in a diminution of the side effects traditionally described with dronabinol capsules thus in a more optimal product for patients.

In 2018, Tetra will perform a comparative pharmacokinetic study of Dronabinol XL AdVersa® versus the listed drug. This study, along with the manufacturing file, will be part of the basis for the Tetra’s planned 505(b)(2) new drug application. The Company expects to complete the analysis of the trial data and announce results in the fourth quarter of 2018, followed by a potential NDA submission in 2019 and will request classification under Schedule III of the Schedules of Controlled Substances.

Dr. Guy Chamberland commented that “in parallel to the preparation of the NDA file, Tetra and IntelGenx will continue the development of PPP002 (Dronabinol XL AdVersa®) as an adjunct therapy for opioid sparing in chronic cancer pain. The commercialization of Dronabinol XL AdVersa® will allow the co-development team to focus its attention on the clinical development activities in opioid sparing. Once completed these Phase III clinical trials will allow Tetra to submit supplements to the NDA and expand the indications of drug approval.”

1: Completion of NDA file expected late 2018/early 2019 followed by a 505(b)(2) NDA submission 1 year ahead of original plans.

2: https://www.transparencymarketresearch.com/cinv-market.html

Market Info CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)2:

According to market research by the International Agency for Research on Cancer (IARC), in 2012, there were 14 million new cases of cancer diagnosed and approximately 4 million people per year receiving chemotherapy globally. CINV affects nearly 70-80% of patients undergoing chemotherapy.

505(b)(2) New Drug Application:

The 505(b)(2) application is one of three established types of new drug application (NDA). It is defined in The Federal Food Drug and Cosmetics Act (FDC Act) as an NDA containing investigations of safety and effectiveness that are being relied upon for approval and were not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. These applications rely in part on the FDA’s findings of safety and/or effectiveness for a previously approved drug (Marinol®(Dronabinol capsules)).

The 505(b)(2) NDA also differs from an abbreviated NDA (ANDA) for generic drugs (Section 505(j) of the FDC Act). An ANDA is an application containing information to demonstrate that the new product is identical to a previously approved product.

About IntelGenx:

IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.

About PPP002 /Dronabinol XL AdVersa®:

PPP002 /Dronabinol XL AdVersa® is a sustained release formula of THC in the form of a buccally absorbed tablet.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Correction to Tetra Bio-Pharma’s previous press release announcing Stock Options Grants

Company also wishes to announce a correction to the information disclosed in its press release dated October 4th, 2017 regarding the grant of an aggregate of 1,400,000 incentive stock options to certain members of its board of directors (“Board of Directors“) and executive officers on October 3rd, 2017. Contrary to what was disclosed in such press release, such grant was not finalized due to a corporate deficiency related to the Board of Directors’ approval.

On November 27, 2017, such deficiency was corrected and, in accordance with the Company’s stock option plan and subject to the approval of the Canadian Securities Exchange, the Board of Directors granted an aggregate of 1,400,000 incentive stock options (“options“) to certain directors, officers and consultants. Each option, vesting immediately upon grant or vesting once certain pre-determined milestones are met, as applicable, entitles the holder thereof to purchase one common share in the capital of the Company at a price of $0.71 per share until November 28, 2018 or November 28, 2021, as applicable.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; the success of the Dronabinol XL AdVersa® product offering; guidance on expected sales volumes associated with the Dronabinol XL AdVersa® product offering; approval by the FDA of the Dronabinol XL AdVersa® clinical trial, competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

PyroGenesis $PYR.ca Announces Q3-2017 Results: Cash Flow Positive on EBITDA (Modified) Basis; Revenues Increase by 7%; Positive Gross Margin of 57%; Current Backlog $7.41MM $HPQ.ca $DDD $SSYS $PRLB

Posted by AGORACOM-JC at 5:22 PM on Tuesday, November 28th, 2017

Pyr header 1

  • Nine month revenues increased 58% to $5.90MM over same period in 2016;
  • Revenues for Q3 2017 increased 7% to $2.03MM over same period in 2016.
  • Gross Margin Before Amortization of Intangible Assets increased to 52.2% in the first 9 months of 2017 from 42.5% posted over the same period in 2016.

MONTREAL, Nov. 28, 2017 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V:PYR) (OTCQB:PYRNF), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma waste-to-energy systems and plasma torch products, is pleased to announce today its financial and operational results for the third quarter ended September 30, 2017.

Results for the first nine (9) months, and Q3, of 2017 reflected the following:

  • Nine (9) month revenues increased 58% to $5.90MM over that of $3.74MM posted in the same period in 2016;
  • Revenues for Q3 2017 increased 7% to $2.03MM over that of $1.9MM posted in the same period in 2016.
  • Gross Margin Before Amortization of Intangible Assets increased to 52.2% in the first 9 months of 2017 from 42.5% posted over the same period in 2016.
  • Gross Margin After Amortization of Intangible Assets increased to 52.2% from 14.5% over the same period in 2016.
  • Gross Margin Before Amortization of Intangible Assets decreased to 57.1% in the third Quarter of 2017, from 64.2% posted in the same period in 2016.
  • Gross Margin After Amortization of Intangible Assets increased to 57.1% from 45.8% over the same period in 2016.
  • Most importantly, for the first nine months of 2017 EBITDA (mod.) improved to a loss of $73.8K as compared to an EBITA (Mod.) loss of $1.1 Million posted in the same period of 2016.
  • For Q3 2017 we posted an EBITA (Mod.) of $92K versus that of $239K for the same period in 2016.
  • Backlog of signed contracts as of the date of this writing is $7.41MM.

At year end 2016, we described the preceding twelve months as being a pivotal year for PyroGenesis as the Company shifted its focus away from being a fabricator of plasma-based systems that produced unique titanium powders, in favour of becoming a producer of metal powders for the Additive Manufacturing Industry (the “Industry”).

Given their unique properties (pure, small, spherical, and uniform) which make them flow like water these powders are greatly sought after in the Industry, particularly for 3D printing. Given this strategic shift, together with the backlog of signed contracts from our non-additive manufacturing business (“Core/Traditional Lines of Business”), we projected that 2017 was shaping up to be a break out year for PyroGenesis, and the first nine months of 2017 have not been disappointing as (i) our powder production system comes on-line (ii) an order for a second DROSRITE™ system from an existing client (iii) US  Navy poised to order a 3rd waste destruction system, and (iv) our chemical warfare weapon destruction system is in the testing phase.

What is important to note is that these results reflect revenues from what we call our Core/Traditional Lines of Business (with little to no revenues from powder sales).  During this period we completed our first powder production system which following certain improvements came on stream in Q1-2017 and ramped up to full production mode during Q3-2017 and is now complete.

We are more convinced than ever before that 2017 is becoming the break out year for which we have positioned the Company for a number of reasons:

  • The healthy gross margins established in 2016 (before consideration of the 2016 write-offs) have improved, and are expected to continue to improve once powder production is in full swing.
  • Established backlog of signed contracts,
  • Our Core/Traditional Lines of Business are poised to contribute significantly to the bottom line and be both profitable and significant in their own right.

The following is a non-exhaustive review of PyroGenesis’ main commercial activities:

A)    Powder Production: The Company has met every major milestone previously announced on the road to making metal powders for the Industry; particularly, the completion of the assembly of its first powder production system; the first powder run; and the completion of ramp-up.

Also, as previously announced in recent press releases, interest has far exceeded management’s expectations as several initial contracts were received for sample powders during the ramp-up phase. Furthermore, the Company announced having signed several agreements with significant players in the Industry, whereby the Company is in discussions regarding the possibility of concluding business relationships or transactions geared to the production of its powders.

These discussions are continuing as the Company actively expands the number, and type, of agreements it is entering into with potential clients.  The Company cannot comment on the specific details of these discussions, or communicate the comments that it has received with regards to the samples provided, other than to say that nothing negative has been reported.

Of note, during the first nine months of 2017, not only was the Company’s first powder production system completed but the Company successfully delivered sample orders for Titanium powder, as well as for Inconel powders. Furthermore, during this period, the Company announced one of the most significant developments to date, possibly even more significant than the Company’s original invention of Plasma Atomization, which is that it has developed a new plasma-based process that provides significant control over its particle size distributions with little to no waste and which, in turn, has enabled the production of MIM cut powders in quantity.

The current system is the first of many PyroGenesis expects to make in order to address an increasing need for metal powders in the Industry1.

B)     DROSRITETM:   As the Company positioned itself, during the first 9 months of 2017, to become a significant powder producer to the Additive Manufacturing Industry, it also positioned its DROSRITETM Furnace System to become a fully commercial product line in and of its own right.

The DROSRITETM Furnace System was proven at a North American customer’s Mexican facility during the first half of 2016.  Soon thereafter, a successful demonstration of the DROSRITE™ System took place in the Middle East, following which an unsolicited request to exclusively market the process in the region was received, and is, as of this writing, in the closing months of being concluded. The Company has also received a request to demonstrate DROSRITE’s™ capabilities in India in early 2018. This flurry of activity and interest for the DROSRITE™ System resulted in the Company dedicating a full time business development manager to market the DROSRITE™ System.

With the recent announced reorder for a DROSRITE™ system by an existing client, management believes it has succeeded in positioning DROSRITE™ as a fully commercial product line.

The market potential for PyroGenesis’ DROSRITE™ System from aluminium dross alone exceeds $400MM.

C)  HPQ: On August 2, 2016, PyroGenesis announced that it had signed contracts totalling CAN$8,260,000 with HPQ Silicon Resources Inc., formally Uragold Bay Resources Inc. (“HPQ”) for the sale of IP and to provide a 200 metric tonne (MT) per year PUREVAPTM pilot system to produce silicon metal directly from quartz. Of particular note, if successful, PyroGenesis benefits from a 10% royalty on all revenues derived from the use of this system by HPQ, subject to annual minimums.

D)  Chemical Warfare Destruction System: The Company recently announced that PyroGenesis has, in coordination with the US-based Southwest Research Institute (SwRI), successfully completed long-duration performance tests using the Company’s tactical Plasma Arc Chemical Warfare Agents Destruction System (“PACWADS”) against surrogate chemical warfare agent material. These tests supported the Defense Advanced Research Projects Agency (DARPA) Agnostic Compact Demilitarization of Chemical Agents (ACDC) program and far exceeded minimum requirements with over 99.9999% destruction efficiency.  The PACWADS has been delivered to the testing site and is currently going through final testing using real chemical warfare agents.  The completion of these tests has been delayed due to unrelated program testing schedules. The testing timeline is out of the Company’s control but now looks like it will be concluded in early 2018.

E)   Other Contracts:  The Company is in discussions relative to other contracts such as a third order for a PAWDS for a New US Aircraft Carrier which is expected to be ordered sometime in the first half of 2018 with an estimated value of approximately $6MM and the sale of the Company’s SPARC system.

Management remains focused on reducing PyroGenesis’ dependency on long-cycle projects by developing a strategic portfolio of volume driven, high margin/low risk products that resolve specific problems within niche markets, and doing so by introducing these plasma-based technologies to industries that have yet to consider such solutions.

Management is also actively targeting recurring revenue opportunities that will generate a growing, and profitable, regular cash flow to the Company.

PyroGenesis has one of the largest concentrations of plasma expertise in the world, with over 250 years of accumulated technical experience and 54 patents (issued/pending), combined with unique relationships with major universities performing cutting edge plasma research and development, which positions the Company well to execute upon its various strategies.

Financial Summary

Revenues

The Company posted revenues of $2,026,557 in the third quarter of 2017 (“Q3, 2017”), representing an increase of 7% compared with $1,902,748 recorded in the third quarter of 2016 (“Q3, 2016”). Revenue recorded in Q3 2017 was generated primarily from (i) the development of a vacuum arc reducing process to convert Silica into high purity Silicon metal, (ii) manufacture and further field testing of Tactical PACWADS, the first mobile plasma system for destruction of chemical warfare agents under contract with an international military consortium, (iii) the demonstration of the viability of PyroGenesis’ existing plasma chemical warfare agent destruction platform with locally available materials, for the complete eradication of chemical warfare agents without creating hazardous by-products, and (iv) support services related to PAWDS-Marine systems supplied to the US Navy.

Cost of Sales and Services and Gross Margins

Cost of sales and services before amortization of intangible assets was $870,352 in Q3, 2017, representing an increase of 28% compared with $682,105 in Q3, 2016. Total costs of sales and services, was $870,352 representing a decrease of 16% compared with $1,031,373 in Q3, 2016.

Various factors, including, but not limited to, the mix of long and short-term manufacturing projects, project complexity and scale, and project R&D content, may significantly impact both the composition and overall level of cost of sales and services reported in a given period, as the mix of labor, materials and subcontracts may be significantly different.

The costs incurred in Q3, 2017 are primarily attributable to the work completed under PyroGenesis’ project to develop a vacuum arc reducing process to convert Silica into high purity Silicon metal, work completed on the tactical mobile plasma system for destruction of chemical warfare agents under contract with an international military consortium, and support services related to PAWDS Marine systems supplied to the US Navy.

Investment tax credits recorded against cost of sales are primarily related to client funded projects that qualify for tax credits from the provincial government of Quebec. Qualifying tax credits increased to $88,338 in Q3, 2017, compared with $16,354 in Q3, 2016. This represents an increase of 440% quarter-over-quarter. The Company continues to make investments in research and development projects incorporating the involvement of strategic partners and government bodies.

In Q3, 2017, the gross margin before amortization of intangible assets was $1,156,205, which represents 57% of revenue. This compares with a gross margin before amortization of intangible assets of $1,220,643 (64% of revenue) for Q3, 2016.

The amortization of intangible assets of Nil in Q3, 2017 ($349,268 in Q3, 2016) relates to the licenses and know-how purchased in 2011 from a company under common control. This expense is a non-cash item and the underlying asset was fully amortized by December 31, 2016.

Selling, General and Administrative Expenses

Selling, general and administrative expenses (“SG&A”) for Q3, 2017 were $1,160,752, representing a decrease of 17% compared with $1,397,638 reported for Q3, 2016. Excluding the costs associated with share-based compensation (a non-cash item in which options vest over a four-year period), SG&A expenses increased by 4% in Q3, 2017 compared with Q3, 2016.

The increase in SG&A expenses is attributable to the net effect of (i) an increase of 13% in employee compensation, (ii) a decrease of 31% for professional fees, primarily due to a decrease in accounting fees and deferred patent expenses, (iii) an increase of 16% in office and general expenses, due to an increase in computers and internet expenses, (iv) travel costs increased by 157%, due to an increase in travel abroad, (v) depreciation on property and equipment decreased by 12%, asset under development in Q3 2017 will begin to be depreciated when the asset is available or ready for use, (vi) government grants increased by 100% due to a higher level of activities supported by such grants, (vii) other expenses increased by 31%, primarily due to the higher cost of freight and shipping, and (viii) a decrease in share base payments of 65%  primarily due to the vesting structure of the stock option plan and the stock options exercised to date.

Total Comprehensive Loss

The comprehensive loss for Q3, 2017 was $360,083 compared to a loss of $717,041 in Q3, 2016, representing a decrease of 50% quarter-over-quarter.

The decrease of $356,958 in the comprehensive loss in Q3, 2017 is primarily attributable to: (i) an increase in product and service related revenue of $123,809, (ii) an increase in cost of sales and services totaling $188,249 as explained above (iii) a decrease in amortization of intangible assets of $349,268, (iv) a decrease in SG&A expenses of $236,886 as explained above, (v) an increase in R&D expenses of $37,668 primarily due to the fact that many of the Company’s engineering and R&D resources were concentrated on activities within projects under construction for clients, with such costs being recorded within cost of sales, (vi) an increase in net finance costs of $127,090 due to a decrease in the fair value of investments of $115,513 compared to the same period in 2016.

EBITDA

The EBITDA loss in Q3, 2017 was $161,094 compared with an EBITDA loss of $176,553 for Q3, 2016, representing a decrease of 9%.

EBITDA (Mod.) gain in Q3, 2017 was $91,713 compared with an EBITDA (Mod.) gain of $238,860 for Q3, 2016. The decrease of $147,147 in the EBITDA (Mod.) in Q3, 2017 is mainly attributable to the decreased comprehensive loss of $356,958, a decrease in depreciation on property and equipment of $3,808, a decrease of $349,268 in amortization of intangible assets, an increase in finance charges of $11,577, a decrease in share-based payments of $278,119, and a decrease in the fair value of investments of $115,113.

Liquidity

As at September 30, 2017, the Company had cash on hand of $317,931 and negative working capital of $5,590,101 compared with a cash balance of $385,257 and negative working capital of $2,079,353 as at December 31, 2016.

About PyroGenesis Canada Inc.
PyroGenesis Canada Inc. is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. PyroGenesis provides engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (3D printing), oil and gas, and environmental industries.  PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization with a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility. Its core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Its operations are ISO 9001:2008 certified, and have been ISO certified since 1997. PyroGenesis is a publicly-traded Canadian company on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace (Ticker Symbol: PYRNF). For more information, please visit www.pyrogenesis.com

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this press release.

For further information: Rodayna Kafal, VP, Investor Relations and Communications, Phone: (514) 937-0002, E-mail: [email protected] or [email protected]

FEATURE: Explor Resources $EXS.ca Flagship Hosts NI 43-101 Resource – 609K Oz Indicated , 470K Oz Inferred $EXN.ca $HBE.ca $OSK.ca

Posted by AGORACOM-JC at 4:03 PM on Tuesday, November 28th, 2017

Why Explor Resources?

  • Flagship Property Offers The Following:
  • NI 43-101 Resource – 609,000 oz Indicated / 470,000 Inferred
  • Property Is 13 KM From Downtown Timmins
  • 2nd Project 43-101 Open Pit Resource
  • 1.4 MILLION T Indicated @ 1.38% Copper
  • 2.09 MILLION T Inferred @ 1.26% Copper